Ads
related to: Moderna
Search results
Moderna Makes Big Play for Big Tech Talent
The Wall Street Journal· 1 day agoCIO Brad Miller has been replacing IT outsourced during the pandemic with a full-time in-house staff as the biotech looks to roll out 15 new products...
What's Going On With Moderna Stock Today? - Moderna (NASDAQ:MRNA)
Benzinga· 22 hours agoModerna Inc. MRNA shares are trading lower Tuesday. The stock may be pulling back after gaining on bird flu concerns last week and predictions for a slight rise in COVID-19 ...
Unveiling Moderna (MRNA)'s Value: Is It Really Priced Right? A C
Guru Focus· 1 day agoModerna Inc (MRNA, Financial) recently experienced a significant daily loss of 7.74%, yet it boasts a 3-month gain of 72.72%. This analysis aims to explore Moderna ...
...Invest Scoops Up Shares Of AMD And Palantir — Dumps Moderna Stock Worth $4.4M - ARK Genomic...
Benzinga· 14 hours agoThese trades reflect Ark’s strategic adjustments amidst market movements. The AMD Trade Ark bought...
Heard on the Street: Moderna Got a Boost From Bird Flu, but Don’t Count Your Chicks
The Wall Street Journal· 6 days agoModerna, BioNTech, CureVac and Novavax have added billions of dollars in combined market...
Moderna and Pfizer In Talks With U.S. To Make a Bird Flu Vaccine
Barrons.com· 7 days agoFEATURE Moderna and Pfizer are in talks with the federal government over a potential avian flu...
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names
InvestorPlace· 7 hours agoBiotech stocks are not for the faint of heart. Between juggling FDA approvals, new product pipelines...
Cathie Wood's ARK buys AMD, sells Moderna in latest stock trades By Investing.com
Investing.com· 17 hours agoCathie Wood's ARK buys AMD, sells Moderna in latest stock trades
Why Vaccine Stocks Rallied This Week
The Motley Fool via AOL· 5 days agoShares of vaccine stocks Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and BioNTech SE (NASDAQ: BNTX) rallied this week, appreciating 23.4%, 16.4%, and...
Should You Buy This Stock After a Regulatory Setback? | The Motley Fool
The Motley Fool· 3 days agoThe past two-and-a-half years have been rough for Moderna (MRNA 1.58%). The company is developing...
